MPW241115P4000
- 0.02
- -0.01-33.33%
Medical Properties Trust Inc Newsroom
Colliers Securities Maintains Medical Properties Trust Inc(MPW.US) With Buy Rating, Maintains Target Price $6.5
Barry Oxford's Optimistic Buy Rating on Medical Properties Trust Amid Strategic Tenant Resolutions
BofA Securities Maintains Medical Properties Trust Inc(MPW.US) With Sell Rating, Cuts Target Price to $3
Mizuho Securities Maintains Medical Properties Trust Inc(MPW.US) With Hold Rating, Cuts Target Price to $6
Truist Financial Maintains Medical Properties Trust Inc(MPW.US) With Hold Rating, Maintains Target Price $6
Medical Properties Trust Price Target Announced at $6.50/Share by Colliers Securities
Medical Properties Trust Raised to Buy From Neutral by Colliers Securities
Medical Properties Trust Analyst Ratings
Colliers Securities Upgrades Medical Properties Trust Inc(MPW.US) to Buy Rating, Raises Target Price to $6.5
Buy Rating for Medical Properties Trust: Strategic Resilience and Positive Financial Outlook
Mizuho Securities Maintains Medical Properties Trust Inc(MPW.US) With Hold Rating, Maintains Target Price $7
Truist Financial Maintains Medical Properties Trust Inc(MPW.US) With Hold Rating, Raises Target Price to $6
Truist Securities Raises Price Target on Medical Properties Trust to $6 From $5, Maintains Hold Rating
Truist Financial Maintains Medical Properties Trust Inc(MPW.US) With Hold Rating, Announces Target Price $5
Colliers Securities Maintains Medical Properties Trust Inc(MPW.US) With Hold Rating, Maintains Target Price $5
Colliers Securities Maintains Medical Properties Trust Inc(MPW.US) With Hold Rating, Maintains Target Price $5
Maintaining Hold on Medical Properties Trust Amid Steward Healthcare Uncertainties and Dividend Cut Concerns
Medical Properties Trust Analyst Ratings
BNP Paribas Exane Downgrades Medical Properties Trust to Neutral From Outperform, Adjusts Price Target to $4 From $6
Truist Securities: Maintaining the Medical Properties Trust (MPW.US) rating, adjusted from holding to holding rating, and adjusted target price from $4.50 to $5.00.